Table 1 Clinical and laboratory findings in patients with rheumatoid arthritis and controls
From: Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis
Clinical and laboratory features | RA patients (N = 90) | Controls (N = 37) | P |
|---|---|---|---|
Age (years) | 52.4 ± 9.9 | 49.0 ± 7.5 | ns |
Females, n (%) | 78/90 (86.7) | 29/37 (78.4) | ns |
BMI (kg/m2) | 25.7 ± 4.3 | 26.2 ± 4.3 | ns |
BMI > 25 kg/m2, n (%) | 48/90 (53.3) | 19/37 (51.4) | ns |
Hypertension, n (%) | 28/90 (31.1) | 8/37 (21.6) | ns |
WC (cm) | 86.9 ± 12.3 | 86.2 ± 11.5 | ns |
Increased WCa, n (%) | 34/90 (37.8) | 10/37 (27.0) | ns |
Waist-to-hip ratio | 0.84 ± 0.08 | 0.83 ± 0.08 | ns |
Metabolic syndrome, n (%) | 19/90 (21.1) | 5/37 (13.5) | ns |
ESR (mm/h) | 29.5 (14–44) | 16.0 (10.0–20.0) | 0.000 |
CRP (mg/l) | 5.5 (2.8–15) | 2.5 (1.8–3.9) | 0.000 |
IL-6 (pg/ml) | 7.4 (2.0–18.8) | 2.0 (2.0–2.4) | 0.000 |
MMP3 (ng/ml) | 185 (90–341) | 68 (58–99) | 0.000 |
Total cholesterol (mmol/l) | 5.2 ± 1.3 | 5.5 ± 0.8 | ns |
TGL (mmol/l) | 1.2 (0.8–1.5) | 1.02 (0.84–1.38) | ns |
Blood glucose (mmol/l) | 4.8 ± 0.6 | 4.7 ± 0.8 | ns |
Insulin (pmol/l) | 68.5 (50.2–102.7) | 55.3 (36.0–69.1) | 0.008 |
C-peptide (pmol/l) | 785 (520–1010) | 600 (450–880) | 0.046 |
HOMA2-IR | 1.4 (1.0–2.3) | 1.2 (0.8–1.4) | 0.008 |
HOMA2-IR > 1, n (%) | 67/90 (74.4) | 20/37 (54.1) | 0.025 |
HOMA2-%S | 70 (46–100) | 84 (71.0–132) | 0.010 |
HOMA2-%B | 148 (116–190) | 141 (114–158) | ns |
Proinsulinb (pmol/l) | 3.9 (2.9/5.4) | 2.9 (2.0/3.8) | 0.032 |
SJC | 7 (4–12) | ||
TJC | 3.5 (0–7) | ||
Patient’s global assessment (VAS, mm) | 50 (30–60) | ||
HAQ | 0.6 (0.3–0.9) | ||
DAS28-ESR | 4.8 ± 1.5 | ||
DAS28-ESR ≥ 5.1, n (%) | 46/90 (51.1) | ||
DAS28-ESR ≤ 3.2, n (%) | 20/90 (22.2) | ||
DAS 28-CRP | 4.2 ± 1.5 | ||
Patients treated with GC, n (%) | 59/90 (65.6) | ||
GC, average daily doses (mg/day) | 5 (5–10) | ||
Duration of GC therapy (years) | 4 (2–6) | ||
DMARD c, n (%) | 90/90 (100%) | ||
Patients on biologic drugs, n (%) | 25/90 (27.8) | ||
Rheumatoid factor positive (%) | 53/90 (58.9) | ||
Anti-CCP positive (%) | 63/90 (70.0) |